产品名称：MicroVue C3a Plus EIA** (For C3 activation)

For Research Use Only in the United States. Not for use in diagnostic procedures.

The MicroVue C3a Plus EIA measures the amount of C3a-desArg present in human plasma and serum.

C3a is generated during the activation of the complement system via the classical or alternative pathway. The anaphylatoxin C3a itself is very short lived and in serum is cleaved rapidly to the more stable C3a-desArg. Therefore, quantitation of C3a-desArg allows reliable conclusions about the level of complement activation in a test sample. For convenience, we refer to both forms as C3a. The MicroVue C3a Plus EIA measures concentrations of C3a in human plasma and sera. It uses a proprietary monoclonal antibody to a neo-epitope on C3a to capture C3a in the solid phase. The trapped C3a is subsequently detected by HRP-labeled antibodies to C3a antigens. This test provides a rapid, non-radioactive method for assessing C3a levels. It is designed for investigations into the role and or status of complement activation in numerous research and clinical settings. An EIA for the detection of C3a (C3a-desArg) in human serum and plasma.

References

Sefton, M.V., et al. Using ELISA to evaluate complement activation by reference biomaterials, J Materials Science, 5:622-627, 1994.

Mold, C, Tamerius, J.D., et al. Complement activation during painful crisis in sickle cell anemia, Clinical Immunology and Immunopathology, 70:3,314-320, 1995.

Rinder, C, et al., Blockade of C5a and SC5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation, J. Clin. Invest., 96:3,1564-1572, 1995.

Rollins, et al. Monoclonal Antibodies directed against human C5 and C8 block complement mediated damage of xenogenic cells and organs, Transplantation, 60:11, 1284-1292, 1995.

Sorace, J., et al., Role of atheroma liposomes and malondialdehyde modified low density lipoproteins in complement activation, Pathobiology, 64:73-78, 1996.

Shorey, et al. A macrophage invasion mechanism of mycobacteria, Science, 277:1091-93, 1997.

Yeh, G., et al. A soluble chimeric complement inhibitory protein that possesses both DAF and Factor I cofactor activities, J. Immuno., 158:2872-2881, 1997.